BTG 1640

Drug Profile

BTG 1640

Alternative Names: ABIO-08/01; ABIO-0801; BTG-1640

Latest Information Update: 31 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Reading
  • Developer Abiogen Pharma
  • Class Anxiolytics; Isoxazoles; Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Generalised anxiety disorder; Panic disorder

Most Recent Events

  • 02 Aug 2010 ABIO 08/01 is still in phase II trials for Panic disorder in Italy
  • 23 May 2008 Phase-II clinical trials in Panic disorder in Italy (PO)
  • 18 Mar 2008 This compound is still in phase II trials for Anxiety disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top